AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
78_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
11_CD
Fixed_VBN
asset_NN
investments_NOMZ
Joint_NN
Other_JJ
ventures_NN
investments_NOMZ
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cost_NN
At_PIN
beginning_GER
of_PIN
year_NN
134_CD
46_CD
180_CD
Additions_NOMZ
120_CD
120_CD
Disposals_NN
and_CC
other_JJ
movements_NOMZ
,_,
including_VBG
exchange_NN
54_CD
54_CD
At_PIN
end_NN
of_PIN
year_NN
134 220 354_CD
Share_NN
of_PIN
post-acquisition_JJ
reserves_NN
At_PIN
beginning_GER
and_PHC
end_NN
of_PIN
year_NN
134_CD
134_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2003 220 220_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2002_CD
46_CD
46_CD
The_DT
fair_JJ
values_NN
of_PIN
other_JJ
investments_NOMZ
are_VPRT
not_XX0
materially_RB
different_PRED
from_PIN
their_TPP3
carrying_VBG
values_NN
._.
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Groups_NN
share_VPRT
ownership_NN
trusts_NN
held_VBD [PRIV]
1,668,299_CD
Ordinary_NN
Shares_NN
._.
Share_NN
of_PIN
joint_JJ
venture_NN
assets_NN
and_PHC
liabilities_NOMZ
2003_CD
2002_CD
$_$
m_CD
$_$
m_CD
Gross_NN
assets_NN
174_CD
107_CD
Gross_NN
liabilities_NOMZ
174_CD
107_CD
12_CD
Stocks_NN
2003_CD
2002_CD
$_$
m_CD
$_$
m_CD
Raw_NN
materials_NN
and_PHC
consumables_NN
715_CD
756_CD
Stocks_NN
in_PIN
process_NN
1,206_CD
1,071_CD
Finished_VBN
goods_NN
and_PHC
goods_NN
for_PIN
resale_NN
1,101_CD
766_CD
3,022_CD
2,593_CD
The_DT
2002_CD
stock_NN
analysis_NN
has_VPRT [PEAS]
been_VBN [PASS]
recategorised_VBN
._.
